News | Heart Valve Technology | December 12, 2023

Use of Anticoagulant Drug after Aortic Valve Replacement Lowers Mortality Risk, Mayo Clinic Study Finds

Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.

The use of bioprosthetic aortic valve replacement has increased significantly during the past decade. Among its advantages is that most patients can avoid warfarin for anticoagulation treatment. Even so, research has been conflicting on whether patients would benefit from more aggressive early postoperative anticoagulation treatment.

Mayo Clinic researchers analyzed nationwide data on more than 10,000 patients who underwent bioprosthetic aortic valve replacement. Warfarin use was associated with a 32% reduction in mortality risk. Patients treated with warfarin early postoperatively also had an increased risk of major bleeding events.

"The findings support early warfarin use in appropriately selected patients, such as patients with low bleeding risk," says Hartzell Schaff, M.D., a Mayo Clinic cardiovascular surgeon who contributed to the study. "There’s often reluctance to prescribe anticoagulant treatment early after surgery due to concerns about bleeding and uncertainty about benefits. Our research finds that the small increased hazard of bleeding (4% versus 2.3%) may be an acceptable risk given the benefits in terms of mortality risk as well as reduced risk of thromboembolism."

The Mayo Clinic study analyzed deidentified patient data from 2007 to 2019 using OptumLabs Data Warehouse, which contains claims data of commercially insured and Medicare Advantage enrollees of all ages and races throughout the U.S.

For more information: https://www.mayoclinic.org/


Related Content

News | Endovascular Aortic Repair

June 19, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home June 19, 2024
Home
News | Endovascular Aortic Repair

October 30, 2023 — -egnite, Inc., a leading cardiovascular digital health company, announced today that novel research ...

Home October 30, 2023
Home
News | Endovascular Aortic Repair

December 5, 2022 — Imagen Technologies, Inc. announced the U.S. Food and Drug Administration's 510(k) clearance of the ...

Home December 05, 2022
Home
News | Endovascular Aortic Repair

October 26, 2022 — Thousands of people have new hope for treatment of thoracic aortic arch disease and University ...

Home October 26, 2022
Home
News | Endovascular Aortic Repair

March 22, 2022 – A retrospective evaluation of 600 fenestrated-branched endovascular aortic repairs for the treatment of ...

Home March 22, 2022
Home
News | Endovascular Aortic Repair

February 18, 2022 – Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of ...

Home February 18, 2022
Home
News | Endovascular Aortic Repair

May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a ...

Home May 12, 2021
Home
News | Endovascular Aortic Repair

February 23, 2021 — Medtronic has voluntarily issued a global recall of unused Medtronic Valiant Navion thoracic stent ...

Home February 23, 2021
Home
News | Endovascular Aortic Repair

January 31, 2020 – The Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) released new reporting ...

Home January 31, 2020
Home
News | Endovascular Aortic Repair

January 29, 2020 – The presence of a blood clot on the wall of the aorta in people with abdominal aortic aneurysms (AAA) ...

Home January 29, 2020
Home
Subscribe Now